Get the Stockscreener App
3.09
0.32%
-0.01
After Hours:
3.09
Exagen Inc stock is traded at $3.09, with a volume of 249.33K.
It is down -0.32% in the last 24 hours and up +0.98% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$3.10
Open:
$3.14
24h Volume:
249.33K
Relative Volume:
0.79
Market Cap:
$74.60M
Revenue:
$66.58M
Net Income/Loss:
$-19.95M
P/E Ratio:
-3.3594
EPS:
-0.9198
Net Cash Flow:
$-14.27M
1W Performance:
+13.19%
1M Performance:
+0.98%
6M Performance:
-70.09%
1Y Performance:
-50.56%
1-Day Range:
$3.03
$3.25
1-Week Range:
$2.65
$3.25
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.09 | 74.84M | 66.58M | -19.95M | -14.27M | -0.9198 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
How Exagen (XGN) returns capital to shareholders | Q4 2025: Earnings Fall ShortEarnings Revision - Newser
annualreportproof.htm - SEC.gov
Exagen (NASDAQ: XGN) outlines 2026 shareholder meeting, board elections and say-on-pay - Stock Titan
Exagen announces resale of up to 1.15M shares - MSN
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 - The Manila Times
Exagen schedules May 11 earnings call before market open, 8:30 ET - Stock Titan
Exagen (XGN) to Release Quarterly Earnings on Monday - MarketBeat
Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest - MarketBeat
Exagen Announces Board Resignation and Committee Restructuring - The Globe and Mail
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ana Hooker resigns from Exagen Board; board size falls to seven - TradingView
Board reshuffle at Exagen (NASDAQ: XGN) as Ana Hooker steps down - Stock Titan
Exagen (NASDAQ: XGN) director reports 7,500 restricted stock units - Stock Titan
XGN Maintained by Canaccord Genuity -- Price Target Lowered to $8.00 - GuruFocus
Exagen (NASDAQ:XGN) Cut to "Sell" at Wall Street Zen - MarketBeat
Does Exagen (XGN)’s 200%+ upside potential make it one of the best penny stocks set to explode? - MSN
Exagen (XGN) Stock vs Peers (Smart Money Flows) 2026-04-15Trending Momentum Stocks - Newser
Exagen Inc. (NASDAQ:XGN) Short Interest Update - MarketBeat
Exagen Inc stock (US30063K1051): Is its autoimmune testing edge strong enough to unlock new upside? - AD HOC NEWS
Aug Intraday: Will Exagen Inc benefit from current market trendsQuarterly Market Summary & Daily Stock Trend Reports - baoquankhu1.vn
Exagen (XGN) price target decreased by 21.78% to 10.03 - MSN
Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode? - Insider Monkey
5 Stocks Under $5 That Will Explode - Insider Monkey
BTIG Maintains Exagen (XGN) Buy Recommendation - MSN
Will Exagen Inc benefit from geopolitical trends2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
How does news flow impact Exagen (XGN) Stock | Price at $2.97, Down 1.00%Most Watched Stocks - Newser
Is Exagen (XGN) Stock Consolidating | Price at $3.20, Up 4.58%Cycle Analysis - Newser
Exagen (XGN) Price Target Increased by 12.20% to 13.41 - MSN
XGN PE Ratio & Valuation, Is XGN Overvalued - Intellectia AI
XGN Technical Analysis & Stock Price Forecast - Intellectia AI
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CEO Change: Is Exagen Inc benefiting from innovation trendsMarket Growth Review & Reliable Entry Point Trade Alerts - baoquankhu1.vn
How Analyst Resets Are Reshaping The Exagen (XGN) Investment Story - finance.yahoo.com
Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation pu - AD HOC NEWS
Stop Loss: Is Exagen Incs growth already priced inGap Up & High Accuracy Trade Alerts - baoquankhu1.vn
Exagen (XGN) director lists 7,500 restricted stock units in Form 3 - Stock Titan
Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase - Stock Titan
Exagen (XGN) CEO John Aballi awarded new RSUs and options - Stock Titan
Exagen prices public offering of common stock - MSN
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat - AD HOC NEWS
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell - MarketBeat
Exagen Q4 Earnings Call Highlights - Defense World
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):